Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
López-Díaz de Cerio A, García-Muñoz R, Pena E, Panizo Á, Feliu J, Giraldo P, Rodríguez-Calvillo M, Martínez-Calle N, Grande C, Olave MT, Andrade-Campos M, Bandrés E, Núñez-Córdoba JM, Inogés S, Panizo C. López-Díaz de Cerio A, et al. Among authors: bandres e. Br J Haematol. 2020 Jun;189(6):1064-1073. doi: 10.1111/bjh.16474. Epub 2020 Mar 4. Br J Haematol. 2020. PMID: 32130737 Free article. Clinical Trial.
Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma.
Rioja J, Bandrés E, Rosell Costa D, Rincón A, López I, Zudaire Bergera JJ, García Foncillas J, Gil MJ, Panizo A, Plaza L, Rioja LA, Berián Polo JM. Rioja J, et al. Among authors: bandres e. BJU Int. 2011 Jun;107(11):1833-8. doi: 10.1111/j.1464-410X.2010.09653.x. Epub 2010 Sep 14. BJU Int. 2011. PMID: 20840328
The abrogation of TCR-independent interactions with human serum ensures a selective capture of therapeutic virus-specific CD8+ T-cells by multimer technology in Adoptive Immunotherapy.
Beloki L, Ciáurriz M, Mansilla C, Bandrés E, Rodríguez-Calvillo M, Ramírez N, Olavarría E. Beloki L, et al. Among authors: bandres e. J Immunol Methods. 2013 Oct 31;396(1-2):168-72. doi: 10.1016/j.jim.2013.07.014. Epub 2013 Aug 6. J Immunol Methods. 2013. PMID: 23933324
Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
Ciáurriz M, Beloki L, Zabalza A, Bandrés E, Mansilla C, Pérez-Valderrama E, Lachén M, Rodríguez-Calvillo M, Ramírez N, Olavarría E. Ciáurriz M, et al. Among authors: bandres e. Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12778. Epub 2017 Oct 25. Transpl Infect Dis. 2017. PMID: 28921749
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R, Rodríguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvise M, Viudez A, Ramirez N, Bitarte N, Chopitea A, Gacía-Foncillas J. Zarate R, et al. Among authors: bandres e. Br J Cancer. 2010 Mar 16;102(6):987-94. doi: 10.1038/sj.bjc.6605595. Epub 2010 Mar 9. Br J Cancer. 2010. PMID: 20216541 Free PMC article. Clinical Trial.
74 results